Dose correcting factors in the treatment of erectile dysfunction with viagra
Abstract
28 patients with erectile dysfunction of different origin received viagra (25, 50 or 100 mg depending on the effect and tolerance). The examination on the treatment week 4, 8 and 12 stated a 85% response. It was found that patients with body mass more than 90 kg benefited most in the dose 100 mg. Maximal single dose 100 mg is recommended for patients over 65 years of age. A 100% response was observed in patients with psychogenic and arteriogenic erectile dysfunction. Low effectiveness of viagra in patients with neurogenic erectile dysfunction can be explained by damaged parasympathetic nerve fibers. Thus, in the decision on viagra dose it is advisable to consider the patient's body mass, age and etiology of erectile dysfunction.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 28 participants or records.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.